Crohn's Disease (cont.)

Crohn's disease is a chronic inflammatory disease involving predominantly the small intestine and colon. The symptoms and the activity of the disease can come and go. Even though many effective medications are available to control the activity of the disease, there is as yet no cure for Crohn's disease. Surgery can significantly improve the quality of life in selected individuals, but recurrence of the disease after surgery is common. The disease can have complications, both within and outside of the intestine. Newer treatments are actively being evaluated. A better understanding of the role of genetics and environmental factors in the cause of Crohn's disease may lead to improved treatments and prevention of the disease.

REFERENCES:

1. Caprilli, R and Frieri, G. The dyspeptic macrophage 30 years later: An update in the pathogenesis of Crohns disease. Digestive and Liver Disease (2009) 41, 166-168.

2. Noomen, CG et al. Update on Genetics in Inflammatory Disease. Best Practice and Research Clinical Gastroenterology (2009) 23, 233-243.

3. Lichtenstein, GR et al. Management of Crohns Disease in Adults. The American Journal of Gastroenterology (2009), 1-19.

4. Hanauer, SB. Medical Management of Crohns Disease: Treatment Algorithms 2009. Digestive Diseases (2009) 27, 536-541.

5. Biologic Therapies for Crohns Disease: Update from the 2009 ACG Meeting. Gastroenterology and Hepatology (2010), Vol 6, Iss 1, Supp 2.

6. Sandborn, WJ et al. Certolizumab Pegol for the Treatment of Crohns Disease. The New England Journal of Medicine (2007) 357, 228-238.

7. Ghosh, S et al. Natalizumab for Active Crohns Disease. The New England Journal of Medicine (2003) 348, 24-32.

8. Dignass, A et al. The Second European Evidence-Based Consensus on the Diagnosis and Management of Crohns Disease: Current Management. Journal of Crohns and Colitis (2010) 4, 28-62.

9. Assche, GV et al. The Second European Evidence-Based Consensus on the Diagnosis and Management of Crohns Disease: Special Situations. Journal of Crohns and Colitis (2010) 4, 63-101.

10. Assche, GV et al. The Second European Evidence-Based Consensus on the Diagnosis and Management of Crohns Disease: Definitions and Diagnosis. Journal of Crohns and Colitis (2010) 4, 7-27.

11. Moscandrew, M, Mahadevan, U, and Kane, S. General Health Maintenance in IBD. Inflammatory Bowel Disease (2009) 15, 1399-1409.

12. Juillerat, P et al. Extraintestinal Manifestations of Crohns Disease. Digestion (2007) 76, 141-148.

13. Colombel, JF et al. Adalimumab for the Treatment of fistulas in Patients with Crohns disease. Gut (2009).

14. DHaens, G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: an open randomized trial. Lancet (2008) 371, 660-667.

15. Kader, HA et al. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine activity in children with inflammatory bowel disease. Journal of Clinical Gastroenterology (Jun 2000) 30(4), 409-13.

Previous contributing authors: Dennis Lee, MD and Lori Kam, MD

Last Editorial Review: 11/17/2010

Source: MedicineNet.com
http://www.medicinenet.com/crohns_disease/article.htm